Table 3.
NY-ESO-1 combinatorial immune-based interventions currently in clinical trial.
| NCT number | Other IDs | Interventions | Conditions | Status |
|---|---|---|---|---|
| NCT01946373 | MAT-02|2012-000450-63 | Peptide-pulsed DC vaccine|TILs | Melanoma | Recruiting |
| NCT01176474 | MCC-15651|NCI-8316 | NY-ESO-1157–165/gp100280–288 vaccine|PD-1 inhibitor (Nivolumab)|PD-1 inhibitor (Nivolumab) + CTLA-4 inhibitor (Ipilimumab) | Stage III–IV melanoma | Active, not recruiting |
| NCT01176461 | MCC-15400|NCI-P-7997|CA209-006/007|10-15526-99-01 | Multi peptide vaccine (MART-1, NY-ESO-1, gp100209–217, gp100280–288|PD-1 inhibitor) (Nivolumab) | Melanoma | Active, not recruiting |
| NCT02609984 | IMDZ-C232 | CMB305|PD-L1 inhibitor (Atezolizumab) | Sarcoma | Active, not recruiting |
| NCT03206047 | NCI-2017-01030|I 285416|10017|P30CA016056 | DEC-205/NY-ESO-1 fusion protein vaccine (CDX-1401)|demethylating agent|PD-L1 inhibitor (atezolizumab) | Recurrent fallopian tube carcinoma|ovarian carcinoma|primary peritoneal carcinoma | Recruiting |
| NCT03017131 | i 283616|NCI-2016-01477|P30CA016056|P50CA159981 | NY-ESO-1 TCR-T cells|demethylating agent | Recurrent fallopian tube carcinoma|ovarian carcinoma|primary peritoneal carcinoma | Not yet recruiting |
| NCT01333046 | H-27471-TACTAL|TACTAL | Multi TAA T cells (NY-ESO-1, MAGEA4, PRAME, survivin and SSX2)|decitabine | Hodgkin lymphoma|non-Hodgkin lymphoma|Hodgkin disease | Recruiting |
| NCT01697527 | 12-000153|NCI-2012-01548 | NY-ESO-1 TCR-T cells|NY-ESO-1157–165 peptide-pulsed DC vaccine | Advanced solid tumors | Recruiting |
| NCT03240861 | 15-000511|NCI-2017-00896|Ribas NYESO SCT Cancer|P30CA016042 | NY-ESO-1 TCR-transduced peripheral blood mononuclear cells and peripheral blood stem cells | Advanced solid tumors | Recruiting |
| NCT02650986 | I 258514|NCI-2015-02080|P30CA016056 | NY-ESO-1 TCR-T cells|TGFbDNRII-transduced TILs | Advanced solid tumors | Recruiting |
| NCT03168438 | ADP-0011-008|KEYNOTE-487 | NY-ESO-1c259-T cells|PD-1 inhibitor (pembrolizumab) | Multiple myeloma | Recruiting |
| NCT02775292 | NYM|15-001433|NCI-2016-00201|Ribas NYESO + Nivolumab Cancer|P30CA016042 | NY-ESO-1 TCR-T cells|NY-ESO-1157–165 -pulsed DC vaccine|PD-1 inhibitor (nivolumab) | Advanced solid tumors | Recruiting |
| NCT02070406 | 13-001624|NCI-2014-00221|P30CA016042 | NY-ESO-1 TCR-T cells|NY-ESO-1157–165 pulsed DC vaccine|CTLA-4 inhibitor (ipilimumab) | Advanced solid tumors | Recruiting |
CMB305, peptide-pulsed DC vaccine LV305 + G305 recombinant NY-ESO-1 protein vaccine; CDX-1401, DEC-205/NY-ESO-1 Fusion Protein vaccine; DC, dendritic cell; TCR, T cell receptor; TAA, tumor-associated antigen; TILs, tumor-infiltrating lymphocytes; PD-L1, programmed death ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death protein 1.